Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

Takeru Yoshimura, Koh Hei Sonoda, Nobuyuki Ohguro, Yoshiyuki Ohsugi, Tatsuro Ishibashi, Daniel J. Cua, Takashi Kobayashi, Hiroki Yoshida, Akihiko Yoshimura

研究成果: Article

130 引用 (Scopus)

抄録

Objectives. Human endogenous uveitis is one of the sight-threatening diseases associated with variety of systemic disorders, such as Behcet's disease and sarcoidosis. Recently, biosynthesized antibodies against inflammatory cytokines have been recognized to be useful to control the regional inflammation. In this study, we focused on the possibility of IL-6-based biological therapies for endogenous uveitis. We initially confirmed the significant increase of several inflammatory soluble factors including IL-6 in the vitreous fluids from refractory/chronic engogenous uveitis patients. Methods. To investigate the role of IL-6 in the formation of refractory ocular inflammation, we used the mouse experimental autoimmune uveitis (EAU) model. Both IL-6 and IL-23 are required for the development of IL-17-producing helper T subset (Th17) from naïve CD4+T cells. Results. In the EAU model, neither IL-6-deficient mice nor IL-23-deficient mice could induce Th17 cells and the EAU score was decreased in these mice in the entire time course. We also confirmed that systemic administration of anti-IL-6 receptor antibody ameliorates EAU by suppressing both systemic and regional Th17 responses. Conclusions. IL-6 is responsible for causing ocular inflammation, and it is, at least partially, due to IL-6-dependent Th17 differentiation. IL-6 may be a target for therapy of refractory endogenous uveitis in humans.

元の言語English
ページ(範囲)347-354
ページ数8
ジャーナルRheumatology
48
発行部数4
DOI
出版物ステータスPublished - 2009

Fingerprint

Th17 Cells
Uveitis
Interleukin-6
Interleukin-23
Therapeutics
Inflammation
Interleukin-6 Receptors
Biological Therapy
Interleukin-17
Behcet Syndrome
Antibodies
Sarcoidosis
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

これを引用

Yoshimura, T., Sonoda, K. H., Ohguro, N., Ohsugi, Y., Ishibashi, T., Cua, D. J., ... Yoshimura, A. (2009). Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology, 48(4), 347-354. https://doi.org/10.1093/rheumatology/ken489

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. / Yoshimura, Takeru; Sonoda, Koh Hei; Ohguro, Nobuyuki; Ohsugi, Yoshiyuki; Ishibashi, Tatsuro; Cua, Daniel J.; Kobayashi, Takashi; Yoshida, Hiroki; Yoshimura, Akihiko.

:: Rheumatology, 巻 48, 番号 4, 2009, p. 347-354.

研究成果: Article

Yoshimura, T, Sonoda, KH, Ohguro, N, Ohsugi, Y, Ishibashi, T, Cua, DJ, Kobayashi, T, Yoshida, H & Yoshimura, A 2009, 'Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis', Rheumatology, 巻. 48, 番号 4, pp. 347-354. https://doi.org/10.1093/rheumatology/ken489
Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ その他. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2009;48(4):347-354. https://doi.org/10.1093/rheumatology/ken489
Yoshimura, Takeru ; Sonoda, Koh Hei ; Ohguro, Nobuyuki ; Ohsugi, Yoshiyuki ; Ishibashi, Tatsuro ; Cua, Daniel J. ; Kobayashi, Takashi ; Yoshida, Hiroki ; Yoshimura, Akihiko. / Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. :: Rheumatology. 2009 ; 巻 48, 番号 4. pp. 347-354.
@article{15c4c1c954c8400c8a596a035c496a65,
title = "Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis",
abstract = "Objectives. Human endogenous uveitis is one of the sight-threatening diseases associated with variety of systemic disorders, such as Behcet's disease and sarcoidosis. Recently, biosynthesized antibodies against inflammatory cytokines have been recognized to be useful to control the regional inflammation. In this study, we focused on the possibility of IL-6-based biological therapies for endogenous uveitis. We initially confirmed the significant increase of several inflammatory soluble factors including IL-6 in the vitreous fluids from refractory/chronic engogenous uveitis patients. Methods. To investigate the role of IL-6 in the formation of refractory ocular inflammation, we used the mouse experimental autoimmune uveitis (EAU) model. Both IL-6 and IL-23 are required for the development of IL-17-producing helper T subset (Th17) from na{\"i}ve CD4+T cells. Results. In the EAU model, neither IL-6-deficient mice nor IL-23-deficient mice could induce Th17 cells and the EAU score was decreased in these mice in the entire time course. We also confirmed that systemic administration of anti-IL-6 receptor antibody ameliorates EAU by suppressing both systemic and regional Th17 responses. Conclusions. IL-6 is responsible for causing ocular inflammation, and it is, at least partially, due to IL-6-dependent Th17 differentiation. IL-6 may be a target for therapy of refractory endogenous uveitis in humans.",
keywords = "Autoimmunity, Cytokine, Eye, IL-6 receptor, Th17",
author = "Takeru Yoshimura and Sonoda, {Koh Hei} and Nobuyuki Ohguro and Yoshiyuki Ohsugi and Tatsuro Ishibashi and Cua, {Daniel J.} and Takashi Kobayashi and Hiroki Yoshida and Akihiko Yoshimura",
year = "2009",
doi = "10.1093/rheumatology/ken489",
language = "English",
volume = "48",
pages = "347--354",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

AU - Yoshimura, Takeru

AU - Sonoda, Koh Hei

AU - Ohguro, Nobuyuki

AU - Ohsugi, Yoshiyuki

AU - Ishibashi, Tatsuro

AU - Cua, Daniel J.

AU - Kobayashi, Takashi

AU - Yoshida, Hiroki

AU - Yoshimura, Akihiko

PY - 2009

Y1 - 2009

N2 - Objectives. Human endogenous uveitis is one of the sight-threatening diseases associated with variety of systemic disorders, such as Behcet's disease and sarcoidosis. Recently, biosynthesized antibodies against inflammatory cytokines have been recognized to be useful to control the regional inflammation. In this study, we focused on the possibility of IL-6-based biological therapies for endogenous uveitis. We initially confirmed the significant increase of several inflammatory soluble factors including IL-6 in the vitreous fluids from refractory/chronic engogenous uveitis patients. Methods. To investigate the role of IL-6 in the formation of refractory ocular inflammation, we used the mouse experimental autoimmune uveitis (EAU) model. Both IL-6 and IL-23 are required for the development of IL-17-producing helper T subset (Th17) from naïve CD4+T cells. Results. In the EAU model, neither IL-6-deficient mice nor IL-23-deficient mice could induce Th17 cells and the EAU score was decreased in these mice in the entire time course. We also confirmed that systemic administration of anti-IL-6 receptor antibody ameliorates EAU by suppressing both systemic and regional Th17 responses. Conclusions. IL-6 is responsible for causing ocular inflammation, and it is, at least partially, due to IL-6-dependent Th17 differentiation. IL-6 may be a target for therapy of refractory endogenous uveitis in humans.

AB - Objectives. Human endogenous uveitis is one of the sight-threatening diseases associated with variety of systemic disorders, such as Behcet's disease and sarcoidosis. Recently, biosynthesized antibodies against inflammatory cytokines have been recognized to be useful to control the regional inflammation. In this study, we focused on the possibility of IL-6-based biological therapies for endogenous uveitis. We initially confirmed the significant increase of several inflammatory soluble factors including IL-6 in the vitreous fluids from refractory/chronic engogenous uveitis patients. Methods. To investigate the role of IL-6 in the formation of refractory ocular inflammation, we used the mouse experimental autoimmune uveitis (EAU) model. Both IL-6 and IL-23 are required for the development of IL-17-producing helper T subset (Th17) from naïve CD4+T cells. Results. In the EAU model, neither IL-6-deficient mice nor IL-23-deficient mice could induce Th17 cells and the EAU score was decreased in these mice in the entire time course. We also confirmed that systemic administration of anti-IL-6 receptor antibody ameliorates EAU by suppressing both systemic and regional Th17 responses. Conclusions. IL-6 is responsible for causing ocular inflammation, and it is, at least partially, due to IL-6-dependent Th17 differentiation. IL-6 may be a target for therapy of refractory endogenous uveitis in humans.

KW - Autoimmunity

KW - Cytokine

KW - Eye

KW - IL-6 receptor

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=63249084553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249084553&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ken489

DO - 10.1093/rheumatology/ken489

M3 - Article

C2 - 19164426

AN - SCOPUS:63249084553

VL - 48

SP - 347

EP - 354

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 4

ER -